tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ALT Stock Latest News

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Press ReleasesCORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
9d ago
ALT
Altimmune presents results of Phase 2 MRI-based body composition sub-study
PremiumThe Fly
Altimmune presents results of Phase 2 MRI-based body composition sub-study
9d ago
ALT
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
PremiumPress Releases
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
9d ago
ALT
Altimmune call volume above normal and directionally bullish
PremiumThe Fly
Altimmune call volume above normal and directionally bullish
15d ago
ALT
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
PremiumPress Releases
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
16d ago
ALT
Altimmune call volume above normal and directionally bullish
PremiumThe FlyAltimmune call volume above normal and directionally bullish
24d ago
ALT
Altimmune call volume above normal and directionally bullish
Premium
The Fly
Altimmune call volume above normal and directionally bullish
1M ago
ALT
David Drutz to Exit Altimmune Board at Next Annual Meeting
Premium
Company Announcements
David Drutz to Exit Altimmune Board at Next Annual Meeting
1M ago
8K
ALT
B. Riley remains buyer of Altimmune into conference updates
PremiumThe Fly
B. Riley remains buyer of Altimmune into conference updates
1M ago
ALT
Altimmune reports Q2 EPS (35c), consensus (34c)
PremiumThe Fly
Altimmune reports Q2 EPS (35c), consensus (34c)
1M ago
ALT
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
PremiumPress Releases
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
1M ago
ALT
ALT Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ALT Earnings this Week: How Will it Perform?
1M ago
ALT
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
PremiumPress ReleasesAltimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
2M ago
ALT
Altimmune announces publication of study of pemvidutide in MASLD
Premium
The Fly
Altimmune announces publication of study of pemvidutide in MASLD
2M ago
ALT
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Premium
Press Releases
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
2M ago
ALT
B. Riley reiterates Buy on Altimmune, Arrowhead after danuglipron given nod
PremiumThe Fly
B. Riley reiterates Buy on Altimmune, Arrowhead after danuglipron given nod
2M ago
ALT
PFE
Altimmune management to meet virtually with B. Riley
PremiumThe Fly
Altimmune management to meet virtually with B. Riley
2M ago
ALT
Altimmune to Participate at Leerink Partners Therapeutics Forum
PremiumPress Releases
Altimmune to Participate at Leerink Partners Therapeutics Forum
3M ago
ALT
Class Action Lawsuit against Altimmune, Inc. (NASDAQ:ALT)
PremiumMarket News
Class Action Lawsuit against Altimmune, Inc. (NASDAQ:ALT)
3M ago
ALT
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
3M ago
ALT
WVE
Altimmune jumps after NY Post highlights this week’s weight loss data
Premium
The Fly
Altimmune jumps after NY Post highlights this week’s weight loss data
3M ago
ALT
Altimmune jumps 5% to $6.57 after New York Post highlights weight loss drug
Premium
The Fly
Altimmune jumps 5% to $6.57 after New York Post highlights weight loss drug
3M ago
ALT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >